Among ongoing clinical trials for glioblastoma, phase I clinical trial studying the effects of anti-PD-1 and anti-CTLA-4 combination therapy with angiogenesis-blocking antibody (bevacizumab) for recurrent glioblastoma (NCT02017717) and a number of studies of DC vaccines, peptide vaccine, CD133-targeting, and vaccine with glioma-associated antigens in recurrent and newly diagnosed glioblastoma are in progress (NCT02010606, NCT02149225, NCT02049489, NCT01808820, NCT02078648). This evidence concerns the gene CTLA4 and glioblastoma.